Nevertheless, the meta-analysis included high-quality RCTs without indication of publication bias, providing compelling evidence for the safety and efficacy of EGFR-TKIs plus anti-VEGFR combination therapy in advanced NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.